RA Capital Management’s LENZ Therapeutics LENZ Stock Holding History

RA Capital Management’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$23.7M	Hold	4,178,823	–	–	0.21%	59
2026 Q1	$38.2M	Hold	4,178,823	–	–	0.41%	41
2025 Q4	$66.9M	Hold	4,178,823	–	–	0.69%	29
2025 Q3	$195M	Hold	4,178,823	–	–	2.4%	12
2025 Q2	$122M	Hold	4,178,823	–	–	2.06%	13
2025 Q1	$107M	Hold	4,178,823	–	–	1.79%	13
2024 Q4	$121M	Hold	4,178,823	–	–	1.61%	16
2024 Q3	$99.2M	Hold	4,178,823	–	–	1.14%	26
2024 Q2	$72.3M	Hold	4,178,823	–	–	0.96%	30
2024 Q1	$93.3M	Buy	+4,178,823	New	+$86.9M	1.19%	25
2022 Q2	–	Sell	-385,481	Closed	-$13.8M	–	101
2022 Q1	$13.8M	Hold	385,481	–	–	0.3%	68
2021 Q4	$33.5M	Hold	385,481	–	–	0.59%	50
2021 Q3	$44.2M	Hold	385,481	–	–	0.61%	42
2021 Q2	$82.9M	Buy	+385,481	New	+$67.1M	1.33%	23

Other funds holding LENZ

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

7IH

72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

RA Capital Management's LENZ Position: Q2 2026 in Review

RA Capital Management held its LENZ Therapeutics (LENZ) position steady in Q2 2026 at 4,178,823 shares worth $23.7M. The position accounts for 0.21% of the portfolio, ranked #59.

RA Capital Management first reported a position in LENZ in Q2 2021 and has held it in 14 quarters since. The position peaked at $195M in Q3 2025. 144 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

RA Capital Management held 4,178,823 shares of LENZ Therapeutics worth $23.7M as of Q2 2026.
RA Capital Management left its LENZ Therapeutics share count unchanged in Q2 2026.
LENZ Therapeutics made up 0.21% of RA Capital Management's portfolio in Q2 2026, its #59 holding.
RA Capital Management first reported a position in LENZ Therapeutics in Q2 2021 and has held it in 14 quarters since.
RA Capital Management's LENZ Therapeutics position peaked at $195M in Q3 2025.
144 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on RA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.